Abbott's New Defibrillation Lead Gains FDA and CE Mark Approvals

Abbott has secured FDA approval and CE Mark in Europe for its UltiSynq™ defibrillation lead. This innovative device is designed for implantation in the left bundle branch area, enabling both cardiac pacing and defibrillation by leveraging the heart's natural electrical system. This development offers a new option for patients requiring advanced heart rhythm management.